Related content

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

By Romano A.   Chiarenza A.   Consoli U.   Conticello C.   Forte S.   Uccello G.   Vetro C.   Cavalli M.   Coppolino F.   Palumbo G. A.   Di Raimondo F.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1038-1044

Oxford University Press

Access to resources Recommend Favorite

Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

By Chim C.  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 181-182

Springer Publishing Company

Access to resources Recommend Favorite

Bendamustine as a model for the activity of alkylating agents

By Apostolopoulos Christos   Castellano Leandro   Stebbing Justin   Giamas Georgios  

Future Oncology, Vol. 4, Iss. 3, 2008-06 ,pp. : 323-332

Future Medicine

Access to resources Recommend Favorite

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

By Srkalovic Gordan   Elson Paul   Trebisky Beth   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 219-226

Humana Press, Inc

Access to resources Recommend Favorite

Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement

By Capalbo Silvana   Chiefa Antonia   Delia Mario   Diomede Daniela   Liso Vincenzo  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 262-264

Informa Healthcare

Access to resources Recommend Favorite